Neo-Adjuvant Treatment of Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 280
Special Issue Editor
Special Issue Information
Dear Colleagues,
Adjuvant or post-surgery care has always been the norm in breast cancer treatment. After the success of the pioneering clinical trials of adjuvant chemotherapy, adjuvant hormonal therapy was introduced successfully as well. On the other hand, treatment before surgery, neo-adjuvant, was only recommended for large or inflammatory breast cancer. Clinicians preferred to administer adjuvant treatment only after a complete pathological report was obtained following surgery, thus avoiding treatment before curative surgery.
Recently, neo-adjuvant therapy has become popular in many cancer types including melanoma, NSCLC, colon cancer, and more. Breast cancer patients who were HER2 positive were the first to be recommended with neo-adjuvant treatment, without regard to size or any other tumor characteristics. Today, neo-adjuvant chemotherapy or hormonal therapy, or even immunotherapy are frequently recommended for patients with breast cancer. It appears that the advantages of neo-adjuvant treatment are recognized, and its shortcomings are negligible. It is imperative that the biology of the many subtypes of breast cancer and its various stages at diagnosis are investigated in order to offer the patients the best treatment at the correct time.
In this Special Issue of Cancers, we aim to discuss the new indications for neo-adjuvant therapy, with a particular focus on the biology and clinical use of this treatment for breast cancer.
Dr. Raphael Catane
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neo-adjuvant
- breast cancer
- chemotherapy
- hormonal therapy
- immunotherapy
- breast cancer survival
- breast cancer surgery
- Norton–Simon hypothesis
